![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1729130
¼¼°èÀÇ Â÷¼¼´ë ½ÃÄö½Ì ¶óÀ̺귯¸® Á¶Á¦ ½ÃÀå : ½ÃÄö½Ì À¯Çü(Ç¥Àû °Ô³ð ½ÃÄö½Ì, Àü°Ô³ð ½ÃÄö½Ì), Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Next-generation Sequencing Library Preparation Market Size study, by Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing), by Product, by Application, by End-use, and Regional Forecasts 2022-2032 |
¼¼°èÀÇ Â÷¼¼´ë ½ÃÄö½Ì(NGS) ¶óÀ̺귯¸® Á¶Á¦ ½ÃÀå ±Ô¸ð´Â 2023³â ¾à 15¾ï 7,000¸¸ ´Þ·¯¿¡¼ ¿¹Ãø ±â°£ Áß 13.00% ÀÌ»óÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
NGS ¶óÀ̺귯¸® Áغñ´Â Çö´ë À¯ÀüüÇÐÀÇ ÇÙ½ÉÀ̸ç, ½ÃÄö½Ì ¿öÅ©Ç÷ο쿡¼ Áß¿äÇÑ Áغñ ´Ü°è·Î¼ À¯Àü Á¤º¸ Ãâ·ÂÀÇ È¿À²¼º, ±íÀÌ ¹× ǰÁúÀ» Á¿ìÇÏ´Â Áß¿äÇÑ Áغñ ´Ü°èÀÔ´Ï´Ù. NGS°¡ ÀÓ»ó Áø´Ü, ¾Ï ¿¬±¸, °¨¿°º´ ¸ð´ÏÅ͸µ, ³ó¾÷ À¯ÀüüÇÐ µî ´Ù¾çÇÑ ºÐ¾ß·Î È®´ëµÊ¿¡ µû¶ó °·ÂÇϰí 󸮷®ÀÌ ³ôÀ¸¸ç ÀÚµ¿ÈµÈ ¶óÀ̺귯¸® Áغñ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚ¿Í ÀÓ»óÀǵéÀº ÀԷ·®À» ÃÖ¼ÒÈÇϰí, ¿À·ù¸¦ ÁÙÀ̸ç, ¿©·¯ Ÿ°ÙÀ» µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ´Â °£¼ÒÈµÈ ¿öÅ©Ç÷ο츦 ¼±ÅÃÇϰí ÀÖÀ¸¸ç, ÀÌ´Â È®´ëµÇ´Â À¯ÀüüÇÐ »ýŰ迡¼ ¶óÀ̺귯¸® Àüó¸® ±â¼úÀÇ Á߿伺À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀº ¸î °¡Áö º¯ÇõÀûÀÎ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿Í ¸ÂÃã Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ç¥Àû À¯Àüü ½ÃÄö½Ì°ú ÀüÀå À¯Àüü ½ÃÄö½Ì¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ µÎ °¡Áö ¸ðµÎ È¿À²ÀûÀÎ ¶óÀ̺귯¸® Áغñ ÇÁ·ÎÅäÄÝ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Á¦¾à»ç ¹× ¿¬±¸±â°üµéÀº µ¥ÀÌÅÍ ÀçÇö¼º°ú 󸮷®À» Çâ»ó½Ã۱â À§ÇØ Ã·´Ü ½Ã¾à, ÀÚµ¿È Ç÷§Æû ¹× ÅëÇÕ ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñµå ±â¹Ý ³ë¸Ö¶óÀÌÁ¦À̼Ç, Æ®·£½ºÆ÷ÀÚÁ¦(transposase), È¿¼Ò Á¶°¢È µîÀÇ Çõ½Å ±â¼úÀ» ÅëÇØ µ¥ÀÌÅÍÀÇ ¹«°á¼ºÀ» À¯ÁöÇÏ¸é¼ Ã³¸® ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ±â¼úÀû ¹ßÀü¿¡µµ ºÒ±¸ÇÏ°í ½ÃÄö½Ì ÀÎÇÁ¶ó¿¡ ´ëÇÑ Ãʱâ ÅõÀÚ ºñ¿ë°ú ÀϺΠ¶óÀ̺귯¸® Áغñ ŰƮÀÇ ±â¼úÀû º¹À⼺, ¿È ¶Ç´Â ¼Ò·®ÀÇ »ùÇÃÀ» ó¸®ÇÒ ¶§ ¹ß»ýÇÏ´Â ±â¼úÀû º¹À⼺ µîÀÌ ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå »óȲ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ Áß Çϳª´Â ¶óÀ̺귯¸® Áغñ ½Ã½ºÅÛÀÇ ¼ÒÇüÈ ¹× ´ÙÁßÈ ±â´É¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â ´ë±Ô¸ð Áý´Ü ¿¬±¸ ¹× ÀÓ»ó½ÃÇè¿¡¼ NGS¸¦ º¸´Ù È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀ¸·Î ¸¸µå´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ¿©·¯ ½ÃÄö½Ì Ç÷§ÆûÀ» Áö¿øÇϰí Ç÷¾×, FFPE Á¶Á÷, ¹Ì»ý¹° DNA µî ´Ù¾çÇÑ ½Ã·á À¯Çü¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Â ¿ÃÀοø ¶óÀ̺귯¸® Áغñ ŰƮ¸¦ °³¹ßÇϱâ À§ÇØ °æÀïÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¶óÀ̺귯¸® Áغñ ´Ü°èÀÇ Ç°Áú°ü¸®¿¡ ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» ÅëÇÕÇÏ´Â ¿òÁ÷ÀÓÀÌ ÁÖ¸ñ¹Þ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº »ç¿ëÀÚ°¡ ½ÃÄö½Ì °á°ú¸¦ ¿¹ÃøÇϰí ÇÁ·ÎÅäÄÝÀ» ÃÖÀûÈÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÚµ¿È, ÀÎÆ÷¸Åƽ½º, ¼Ò¸ðǰÀÇ Çõ½ÅÀÌ °áÇÕÇÏ¿© ¿¬±¸¿Í ÀÓ»ó ¸ðµÎ¿¡ ÇÊ¿äÇÑ Â÷¼¼´ë ÅøÀÇ ¹°°áÀÌ Àü ¼¼°è¿¡¼ È®»êµÇ°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ Â÷¼¼´ë ½ÃÄö½Ì ¶óÀ̺귯¸® Á¶Á¦ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ °¢Á¾ ¿µÇâ¿äÀÎÀÇ ºÐ¼®, ¹ý±ÔÁ¦ ȯ°æ, ½ÃÀå ±Ô¸ð ÃßÀÌ¡¤¿¹Ãø, °¢Á¾ ±¸ºÐ¡¤Áö¿ª/ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ÀÇ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
The Global Next-generation Sequencing (NGS) Library Preparation Market is valued approximately at USD 1.57 billion in 2023 and is anticipated to grow with a compound annual growth rate of more than 13.00% over the forecast period 2024-2032. NGS library preparation lies at the heart of modern genomics, acting as a critical preliminary step in the sequencing workflow that determines the efficiency, depth, and quality of genetic data output. The process involves the fragmentation of nucleic acids and the addition of specialized adapters to facilitate sequencing. As the applications of NGS broaden across clinical diagnostics, oncology, infectious disease surveillance, and agricultural genomics, the demand for robust, high-throughput, and automation-friendly library preparation solutions is accelerating significantly. Researchers and clinicians are increasingly opting for streamlined workflows that minimize input quantity, reduce errors, and enable simultaneous analysis of multiple targets, all of which amplify the significance of library preparation technologies in the expanding genomics ecosystem.
The market growth is driven by several transformative factors. The rise in demand for precision medicine and personalized therapies has escalated the need for targeted genome and whole genome sequencing-two major applications that depend heavily on efficient library preparation protocols. Pharmaceutical companies and research laboratories are investing in advanced reagents, automation platforms, and integrated systems to enhance data reproducibility and throughput. Furthermore, innovations such as bead-based normalization, transposase-based methods, and enzymatic fragmentation are reducing turnaround times while preserving data integrity. However, despite technological advancements, market growth is partially hindered by challenges like high initial capital expenditure for sequencing infrastructure and the technical complexity associated with some library prep kits, especially when dealing with degraded or limited input samples.
A key trend influencing the landscape is the growing focus on miniaturization and multiplexing capabilities in library prep systems. This shift is aimed at improving the scalability and cost-effectiveness of NGS for large population studies and clinical trials. Companies are racing to develop all-in-one library prep kits compatible with multiple sequencing platforms and adaptable to a wide range of sample types-from blood to FFPE tissue to microbial DNA. Additionally, the integration of machine learning algorithms for quality control during library prep stages is gaining traction. These solutions are enabling end-users to predict sequencing outcomes and optimize protocols, further enhancing reliability. The confluence of automation, informatics, and consumables innovation is thus driving a wave of next-gen tools that address both research and clinical needs across the globe.
Regionally, North America remains the epicenter of the NGS library preparation market, primarily due to its strong presence of genomic research institutions, significant funding from NIH and other agencies, and early adoption of clinical NGS. The United States in particular has established a mature ecosystem of NGS service providers, life science tool manufacturers, and academic collaborators. Europe follows closely, supported by large-scale genomic initiatives in countries like the UK, Germany, and the Netherlands. Meanwhile, Asia Pacific is projected to be the fastest-growing region, spurred by government-led genomic projects in China and India, increasing healthcare investments, and the presence of a growing number of CROs and clinical diagnostic companies. These developments across geographies signify a global shift towards genomics-enabled healthcare and data-driven life sciences.